Key points are not available for this paper at this time.
Rheumatoid arthritis is a common chronic inflammatory and destructive arthropathy that cannot be cured and that has substantial personal, social, and economic costs. The long-term prognosis is poor: 80 percent of affected patients are disabled after 20 years, 1 and life expectancy is reduced by an average of 3 to 18 years. 2 The medical cost of rheumatoid arthritis averages 5, 919 per case per year in the United States3 and approximately £2, 600 per case per year in the United Kingdom. 4 Current slow-acting antirheumatic drugs have limited efficacy and many side effects. Moreover, they do not improve the long-term prognosis of rheumatoid arthritis. . . .
Choy et al. (Thu,) studied this question.